One of the great success stories of the ASX will be celebrating 25 years as a public company with a ceremonial bell ring at the market open on Monday.
Biotech giant CSL - originally Commonwealth Serum Laboratories - was established by the Australian government in 1916 and listed on the ASX in 1994.
Its shares were issued at $2.30 and in the 25 years since they've grown on average by 25.2 per cent each year, including a three-for-one stock split in 2007.
"Staying true to our values has paid dividends for the business, our investors and the people that have benefited from the therapies we make," said CSL chairman Brian McNamee.
CSL is now the third largest publicly listed company in Australia, and the fifth largest biotech company globally, with a market capitalisation of $111 billion and 25,000 employees.
"The IPO was a win-win. It was a mechanism to return funding to the Commonwealth and at the same time, gave us the freedom to chart our own path with a clear mandate to make CSL a commercially relevant organisation," Dr McNamee said.
CSL shares were trading at $244.52 late on Friday afternoon, up 32 per cent for the year.